Markets

Why Sarepta (SRPT) Stock Is Plummeting Today

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Sarepta Therapeutics Inc (NASDAQ: SRPT ) stock is being rocked Thursday following an announcement from the Food and Drug Administration (FDA).

The agency discussed compensation for patients with serious diseases in trials with drugs that have not been yet approved. The sponsor may not charge for indirect costs from sponsors, said the FDA.

In terms of how to charge for a drug, the agency said that a company "may recover only its direct costs associated with making the drug available to the patient."

This affects Sarepta negatively with its drug trial of a Duchenne muscular dystrophy medication

SRPT stock is down 27.8% Thursday.

More From InvestorPlace

The post Why Sarepta (SRPT) Stock Is Plummeting Today appeared first on InvestorPlace .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SRPT

Other Topics

Stocks